Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Pharmazie

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 24380237
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin.

  2012cited by this paper
• Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP‐3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P‐glycoprotein inhibition by myricetin

  2010cited by this paper
• Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4

  2010cited by this paper
• Antiangiogenic effect of licochalcone A.

  2010cited by this paper
• Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats.

  2009cited by this paper
• Effect of hesperidin on the oral pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats

  2009cited by this paper
• The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan.

  2008cited by this paper
• Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells.

  2008cited by this paper
• Licochalcone A isolated from licorice suppresses lipopolysaccharide-stimulated inflammatory reactions in RAW264.7 cells and endotoxin shock in mice

  2008cited by this paper
• Enhanced bioavailability of verapamil after oral administration with hesperidin in rats

  2008cited by this paper
• Effects of morin on the pharmacokinetics of nicardipine after oral and intravenous administration of nicardipine in rats

  2008cited by this paper
• Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.

  2006cited by this paper
• A Rapid HPLC Method for the Determination of Losartan in Human Plasma Using a Monolithic Column

  2005cited by this paper
• Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells.

  2005cited by this paper
• Inhibition of human cytochromes P450 by components of Ginkgo biloba

  2004cited by this paper
• Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells.

  2004cited by this paper
• Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data.

  2003cited by this paper
• Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.

  2002cited by this paper
• Effect of Grapefruit Juice on the Pharmacokinetics of Losartan and Its Active Metabolite E3174 in Healthy Volunteers

  2001cited by this paper
• In vitro evaluation of newly developed chalcone analogues in human cancer cells

  2000cited by this paper
• Active transport of the angiotensin‐II antagonist losartan and its main metabolite EXP 3174 across MDCK‐MDR1 and Caco‐2 cell monolayers

  2000cited by this paper
• Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid.

  2000cited by this paper
• The Effects of Fluvastatin, a CYP2C9 Inhibitor, on Losartan Pharmacokinetics in Healthy Volunteers

  1999cited by this paper
• Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E‐3174

  1999cited by this paper
• The antileishmanial activity of novel oxygenated chalcones and their mechanism of action.

  1999cited by this paper
• Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174

  1998cited by this paper
• Antioxidative and superoxide scavenging activities of retrochalcones in Glycyrrhiza inflata.

  1998cited by this paper
• Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension.

  1997cited by this paper
• Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450.

  1997cited by this paper
• Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans

  1995cited by this paper
• Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.

  1995cited by this paper
• Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.

  1995cited by this paper
• Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine.

  1995cited by this paper
• Anti‐tumorigenic chalcones

  1994cited by this paper
• Licochalcone A, a new antimalarial agent, inhibits in vitro growth of the human malaria parasite Plasmodium falciparum and protects mice from P. yoelii infection

  1994cited by this paper
• Cloning, expression and regulation of angiotensin II receptors.

  1994cited by this paper

• Research Progress and Prospects of Flavonoids in the Treatment of Hyperlipidemia: A Narrative Review

  2025influential citation
• Evaluation of Potential Herb-Drug Interactions Between Shengmai Injection and Losartan Potassium in Rat and In Vitro

  2022cites this paper
• Natural products in licorice for the therapy of liver diseases: Progress and future opportunities.

  2019cites this paper
• Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats

  2018cites this paper
• Assessment of the inhibition potential of Licochalcone A against human UDP-glucuronosyltransferases.

  2016cites this paper
• Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism

  2016cites this paper
• Recent trends in preclinical drug–drug interaction studies of flavonoids — Review of case studies, issues and perspectives

  2015cites this paper
• Effect of commercial Rhodiola rosea on CYP enzyme activity in humans

  2015cites this paper
• Species Differences in the Pharmacokinetic Parameters of Cytochrome P450 Probe Substrates between Experimental Animals, such as Mice, Rats, Dogs, Monkeys, and Microminipigs, and Humans

  2015cites this paper
• Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice.

  2015cites this paper
• In vitro and in vivo Drug-Drug Interaction of Losartan and Glimepiride in Rats and Its Possible Mechanism

  2015cites this paper